MedTrace Logo

Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode

NCT02532660 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2022-06-16

No results posted yet for this study

Summary

Evaluate the therapeutic effects of Escitalopram versus an association of Escitalopram + Trichilia catigua Dry Extract (LABCAT TCJUSS) in the average alteration on depression score measured by the Hamilton Scale (HAM-D).

Conditions

Interventions

DRUG

Escitalopram 10mg

Escitalopram 10mg (1 pill once a day)

DRUG

LABCAT TCJUSS

LABCAT TCJUSS 1000mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night)

DRUG

LABCAT TCJUSS Placebo

LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);

DRUG

Escitalopram Placebo

Escitalopram Placebo (1 pill once a day)

Sponsors & Collaborators

  • Universidade Federal do Ceara

    collaborator OTHER

  • Financiadora de Estudos e Projetos

    collaborator OTHER

  • Laboratório Catarinense SA

    lead INDUSTRY

Principal Investigators

  • Maria Elisabete Moraes · Universidade Federal do Ceara (UFC)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-02
Primary Completion
2022-06-01
Completion
2022-06-01

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02532660 on ClinicalTrials.gov